Latest news with #Enhabit
Yahoo
5 days ago
- Business
- Yahoo
Enhabit Home Health & Hospice Announces Date of 2025 Second Quarter Earnings Call
DALLAS, July 17, 2025--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced it will report its results for the second quarter ended June 30, 2025, on Aug. 6, 2025, and host a webcast and conference call on Aug. 7, 2025. Individuals who would like to participate in the conference call webcast should join 15 minutes before the scheduled start time. Aug. 7, 2025 10 a.m. EDT Toll-free: 888-660-6150 International: 929-203-0843 Conference ID: 5248158 Webcast link: A link to the webcast of the conference call and online replay can be found on Enhabit's investor website. About Enhabit Home Health & Hospice Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 251 home health locations and 113 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit View source version on Contacts Investor relations Bob Okunskiinvestorrelations@ 469-860-6061 Media contact Erin Volbedamedia@ 972-338-5141 Sign in to access your portfolio
Business Wire
6 days ago
- Business
- Business Wire
Enhabit Home Health & Hospice Announces Date of 2025 Second Quarter Earnings Call
DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced it will report its results for the second quarter ended June 30, 2025, on Aug. 6, 2025, and host a webcast and conference call on Aug. 7, 2025. Individuals who would like to participate in the conference call webcast should join 15 minutes before the scheduled start time. Aug. 7, 2025 10 a.m. EDT Toll-free: 888-660-6150 International: 929-203-0843 Conference ID: 5248158 Webcast link: A link to the webcast of the conference call and online replay can be found on Enhabit's investor website. About Enhabit Home Health & Hospice Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 251 home health locations and 113 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit
Business Wire
20-05-2025
- Business
- Business Wire
Enhabit Announces Participation in Goldman Sachs 46th Annual Global Healthcare Conference
DALLAS--(BUSINESS WIRE)-- Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. Enhabit's President and CEO Barb Jacobsmeyer and Chief Financial Officer Ryan Solomon will participate in a fireside chat on Tuesday, June 10, at 10 a.m. EDT. The fireside chat will be webcast live and available for replay at Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 251 home health locations and 113 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit
Business Wire
11-05-2025
- Business
- Business Wire
Enhabit Reports First Quarter 2025 Financial Results
DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the first quarter ended March 31, 2025. 'Enhabit's first quarter 2025 results are a product of steadfast execution of our strategies,' said Barb Jacobsmeyer, president and CEO of Enhabit. 'Home health census grew 3.7% sequentially and hospice census grew 12.3% year over year. The combination of strong growth, improved profitability and continued balance sheet improvements resulted in a leverage ratio now below 4.5 times. This enables us to formally exit the covenant relief period restrictions in our credit agreement and allows us to benefit from improved pricing on our debt and added flexibility going forward.' QUARTERLY PERFORMANCE - CONSOLIDATED Net service revenue of $259.9 million Net income attributable to Enhabit, Inc. of $17.8 million, which includes a gain on sale of investment of $14.7 million, net of tax Adjusted EBITDA of $26.6 million Earnings per share of $0.35 Adjusted diluted earnings per share of $0.10 RECENT COMPANY HIGHLIGHTS Home health non-Medicare admissions increased 7.4% with total admissions growth of 0.7% year over year. When normalizing for leap year and branches closed in Q1, total admission growth was 2.5%. Sequential home health Medicare ADC growth of 1.5%, marking the second consecutive quarter of growth Total home health ADC sequential growth of 3.7% and exited Q1 2025 with ADC above prior year Home health cost per patient day decreased 2.4% year over year Hospice average daily census increased 12.3% year over year Average daily census increased sequentially every month since January 2024 Hospice admissions increased 8.0% year over year Hospice Adjusted EBITDA increased 64.8% year over year Hospice cost per patient day decreased 0.8% year over year One Hospice de novo branch opened in Q1 Consolidated Adjusted EBITDA grew 5.1% year over year and 6.0% sequentially to $26.6 million. Reduced bank debt by $25.0 million in the quarter Bank debt down $60.0 million year over year Leverage ratio below 4.5 times, one quarter earlier than credit agreement required Home office G&A expenses decreased 1.3% due to cost control initiatives FINANCIAL RESULTS Consolidated SEGMENT RESULTS Home health ($ in millions) Q1 '25 vs. '24 2025 2024 Net service revenue: Medicare $114.2 $128.3 (11.0) % Non-Medicare 84.4 82.6 2.2 % Private duty (1) 2.0 2.3 (13.0) % Home health net service revenue 200.6 213.2 (5.9) % Cost of service 103.4 109.9 (5.9) % Gross margin 48.5 % 48.5 % General and administrative expenses 58.4 59.5 (1.8) % Net income attributable to noncontrolling interests 0.5 0.6 (16.7) % Adjusted EBITDA $38.3 $43.2 (11.3) % % Adj. EBITDA margin 19.1 % 20.3 % Operational metrics (actual amounts) Medicare: Admissions 24,044 25,944 (7.3) % Recertifications 15,734 17,652 (10.9) % Completed episodes 38,266 43,171 (11.4) % Average daily census 20,110 21,709 (7.4) % Visits 547,690 632,047 (13.3) % Visits per episode 14.3 14.6 (2.1) % Revenue per episode $2,984 $2,972 0.4 % Non-Medicare: Admissions 33,178 30,881 7.4 % Recertifications 13,133 13,489 (2.6) % Average daily census 21,126 20,541 2.8 % Visits 542,526 571,289 (5.0) % Total: Admissions 57,222 56,825 0.7 % Same-store total admissions growth 0.7 % Recertifications 28,867 31,141 (7.3) % Same-store total recertifications growth (7.3) % Average daily census 41,236 42,250 (2.4) % Visits 1,090,216 1,203,336 (9.4) % Visits per episode 13.9 14.9 (6.7) % Cost per visit $93.5 $90.0 3.9 % Revenue per patient day $54.1 $55.5 (2.5) % Cost per patient day $27.9 $28.6 (2.4) % (1) Private duty represents long-term comprehensive hourly nursing medical care. Expand Hospice ($ in millions) Q1 '25 vs. '24 2025 2024 Net service revenue $59.3 $49.2 20.5 % Cost of service 26.8 24.3 10.3 % Gross margin 54.8 % 50.6 % General and administrative expenses 17.4 15.7 10.8 % Net income attributable to noncontrolling interests 0.1 0.1 — % Adjusted EBITDA $15.0 $9.1 64.8 % % Adj. EBITDA margin 25.3 % 18.5 % Operational metrics (actual amounts) Total admissions 3,274 3,032 8.0 % Same-store total admissions growth 5.2 % Patient days 342,784 308,542 11.1 % Discharged average length of stay 101 104 (2.9) % Average daily census 3,809 3,391 12.3 % Revenue per patient day $173.0 $159.6 8.4 % Cost per patient day $78.2 $78.8 (0.8) % Expand GUIDANCE The Company reaffirmed its full-year 2025 guidance as of May 7, 2025: For additional considerations regarding the Company's 2025 guidance ranges, see the supplemental information posted on the Company's website at CONFERENCE CALL INFORMATION The Company will host an investor conference call at 10 a.m. EDT on May 8, 2025 to discuss its results for the first quarter of 2025. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting Following the call, a replay will be available on the Company's website at ABOUT ENHABIT HOME HEALTH & HOSPICE Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 251 home health locations and 113 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit OTHER INFORMATION The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, and Adjusted free cash flow. For 2025, the Company has modified its methodology of calculating Adjusted free cash flow to exclude the impact of unusual or nonrecurring items on cash income taxes and changes in working capital. The change was made to conform to the Adjusted free cash flow measure with the current definition used by management and the Board of Directors to manage cash flow and evaluate performance. Prior periods presented herein have been recast to conform with the new methodology. The Company believes the non-GAAP financial measures are useful to investors because they facilitate evaluation of core business operating results over multiple periods unaffected by differences in unusual or nonrecurring items. See 'Supplemental Non-GAAP Information' for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Additionally, our Form 10-Q for the three months ended March 31, 2025, provides further information regarding 'unusual or nonrecurring items that are not typical of ongoing operations,' a reconciliation item in our Adjusted EBITDA calculation. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies. The Company is unable to reconcile the guidance for Adjusted EBITDA and Adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and professional fees and other costs or income related to items the Company believes to not be indicative of its ongoing operations. For the same reasons, the Company is unable to address the probable significance of the unavailable information. Note regarding presentation of same-store comparisons The Company uses 'same-store' comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations. Enhabit, Inc. Condensed Consolidated Balance Sheets (Unaudited) (in millions) March 31, 2 025 December 31, 2 024 Assets Current assets: Cash and cash equivalents $ 39.5 $ 28.4 Restricted cash 1.3 1.9 Accounts receivable, net of allowances 160.9 149.2 Prepaid expenses and other current assets 9.6 13.2 Total current assets 211.3 192.7 Property and equipment, net 16.1 17.7 Operating lease right-of-use assets 52.1 52.8 Goodwill 900.0 900.0 Intangible assets, net 53.6 58.1 Other long-term assets 2.8 4.7 Total assets $ 1,235.9 $ 1,226.0 Liabilities and Stockholders' Equity Current liabilities: Current portion of long-term debt $ 22.5 $ 22.8 Current operating lease liabilities 12.8 12.3 Accounts payable 8.0 6.7 Accrued payroll 49.4 37.1 Accrued medical insurance 7.8 5.5 Other current liabilities 41.0 41.8 Total current liabilities 141.5 126.2 Long-term debt, net of current portion 467.3 492.6 Long-term operating lease liabilities, net of current portion 41.0 41.8 Deferred income tax liabilities 12.8 11.5 Total liabilities 662.6 672.1 Commitments and contingencies (See Note 7) Redeemable noncontrolling interests 5.0 5.0 Stockholders' equity: Total Enhabit, Inc. stockholders' equity 543.2 523.5 Noncontrolling interests 25.1 25.4 Total stockholders' equity 568.3 548.9 Total liabilities and stockholders' equity $ 1,235.9 $ 1,226.0 Expand Enhabit, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Three Months Ended March 31, (in millions) 2025 2024 Cash flows from operating activities: Net income $ 18.4 $ 0.9 Adjustments to reconcile net income to net cash provided by operating activities— Depreciation and amortization 6.3 7.8 Amortization of debt-related costs 0.4 0.4 Gain on sale of investment (19.3 ) — Stock-based compensation 4.0 1.8 Deferred income taxes 1.2 (0.5 ) Other — (0.3 ) Changes in assets and liabilities, net of acquisitions— Accounts receivable, net of allowances (11.7 ) (9.7 ) Prepaid expenses and other assets 4.1 3.7 Accounts payable 1.4 1.4 Accrued payroll 11.6 10.7 Other liabilities 1.5 1.1 Net cash provided by operating activities 17.9 17.3 Cash flows from investing activities: Purchases of property and equipment, including capitalized software costs (0.3 ) (1.8 ) Proceeds from sale of investment 21.0 — Other 0.1 0.7 Net cash provided by (used in) investing activities 20.8 (1.1 ) Cash flows from financing activities: Principal payments on debt (25.0 ) (5.0 ) Principal payments under finance lease obligations (0.8 ) (1.0 ) Distributions paid to noncontrolling interests of consolidated affiliates (0.9 ) — Other (1.5 ) (0.6 ) Net cash used in financing activities (28.2 ) (6.6 ) Increase in cash, cash equivalents, and restricted cash 10.5 9.6 Cash, cash equivalents, and restricted cash at beginning of period 30.3 29.8 Cash, cash equivalents, and restricted cash at end of period $ 40.8 $ 39.4 Expand Enhabit, Inc. Supplemental Non-GAAP Information (Unaudited) Three Months Ended March 31, 2025 2024 Diluted earnings per share, as reported $ 0.35 $ 0.01 Adjustments, net of tax: Gain on sale of investment and loss on disposal of assets (0.29 ) — Unusual or nonrecurring items that are not typical of ongoing operations (1) 0.01 0.06 Income tax adjustments (2) 0.03 0.01 Adjusted earnings per share (3) $ 0.10 $ 0.07 Expand (1) Unusual or nonrecurring items in the three months ended March 31, 2025 include costs associated with restructuring activities and severance and nonroutine litigation; in the three months ended March 31, 2024, they include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism. (2) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation and the effect of a valuation allowance recorded against a portion of our deferred tax assets. (3) Adjusted diluted EPS may not sum due to rounding. Expand Three Months Ended March 31, 2025 Adjustments ($ in millions, except per share data) As Reported Gain on Sale of Investment and Loss on Disposal of Assets Unusual or Nonrecurring Items That are Not Typical of Ongoing Operations Income tax Adjustments (4) As Adjusted Adjusted EBITDA (1) $ 26.6 $ — $ — $ — $ 26.6 Interest expense and amortization of debt discounts and fees (9.4 ) — — — (9.4 ) Depreciation and amortization (6.3 ) — — — (6.3 ) Gain on sale of investment and loss on disposal of assets (2) 19.3 (19.3 ) — — — Stock-based compensation (4.0 ) — — — (4.0 ) Unusual or nonrecurring items that are not typical of ongoing operations (3) (1.0 ) — 1.0 — — Income before income taxes 25.2 (19.3 ) 1.0 — 6.9 Income tax (expense) benefit (7.4 ) 4.6 (0.3 ) 1.4 (1.7 ) Net income attributable to Enhabit, Inc. $ 17.8 $ (14.7 ) $ 0.7 $ 1.4 $ 5.2 Adjusted diluted EPS (5) $ 0.35 $ (0.29 ) $ 0.01 $ 0.03 $ 0.10 Adjusted diluted shares 50.8 50.8 Expand (1) Reconciliation to GAAP provided below. (2) Gain on sale of investment resulted from the sale of Medalogix investment. (3) Unusual or nonrecurring items in Q1 2025 include costs associated with restructuring activities and severance and nonroutine litigation. (4) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation and the effect of a valuation allowance recorded against a portion of our deferred tax assets. (5) Adjusted diluted EPS may not sum due to rounding. Expand Three Months Ended March 31, 2024 Adjustments Adjusted EBITDA (1) $ 25.3 $ — $ — $ 25.3 Interest expense and amortization of debt discounts and fees (11.1 ) — — (11.1 ) Depreciation and amortization (7.8 ) — — (7.8 ) Gain on disposal of assets 0.2 — — 0.2 Stock-based compensation (1.8 ) — — (1.8 ) Unusual or nonrecurring items that are not typical of ongoing operations (2) (3.7 ) 3.7 — — Income before income taxes 1.1 3.7 — 4.8 Income tax (expense) benefit (0.9 ) (0.9 ) 0.6 (1.2 ) Net income attributable to Enhabit, Inc. $ 0.2 $ 2.8 $ 0.6 $ 3.6 Adjusted diluted EPS (4) $ 0.01 $ 0.06 $ 0.01 $ 0.07 Adjusted diluted shares 50.4 50.4 Expand (1) Reconciliation to GAAP provided below. (2) Unusual or nonrecurring items in Q1 2024 include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism. (3) Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. (4) Adjusted diluted EPS may not sum due to rounding. Expand Reconciliation of Net Income to Adjusted EBITDA Three Months Ended March 31, ($ in millions) 2025 2024 Net income $ 18.4 $ 0.9 Interest expense and amortization of debt discounts and fees 9.4 11.1 Provision for income taxes 7.4 0.9 Depreciation and amortization 6.3 7.8 Gain on sale of investment and disposal of assets (19.3 ) (0.2 ) Stock-based compensation 4.0 1.8 Net income attributable to noncontrolling interests (0.6 ) (0.7 ) Unusual or nonrecurring items that are not typical of ongoing operations (1) 1.0 3.7 Adjusted EBITDA $ 26.6 $ 25.3 Expand (1) Unusual or nonrecurring items in the three months ended March 31, 2025 include costs associated with restructuring activities and severance and nonroutine litigation; in the three months ended March 31, 2024, they include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism. Expand Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA Three Months Ended March 31, ($ in millions) 2025 2024 Net cash provided by operating activities $ 17.9 $ 17.3 Interest expense, excluding amortization of debt discounts and fees 9.0 10.7 Current portion of income tax expense 6.2 1.4 Change in assets and liabilities (6.9 ) (7.2 ) Net income attributable to noncontrolling interests (0.6 ) (0.7 ) Unusual or nonrecurring items that are not typical of ongoing operations (1) 1.0 3.7 Other — 0.1 Adjusted EBITDA $ 26.6 $ 25.3 Expand (1) Unusual or nonrecurring items in the three months ended March 31, 2025 include costs associated with restructuring activities and severance and nonroutine litigation; in the three months ended March 31, 2024, they include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism. Expand (1) Unusual or nonrecurring items in the three months ended March 31, 2025 include costs associated with restructuring activities and severance and nonroutine litigation; in the three months ended March 31, 2024, they include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism. (2) For 2025 and going forward, adjusted free cash flow will exclude the cash impact of unusual and nonrecurring items from both cash income tax payments (refunds), net and working capital and other. The 2024 calculations have been conformed to the current methodology, which has an impact of less than $0.1 for both Q1 and the full year. Expand (1) Unusual or nonrecurring items in the three months ended March 31, 2025 include costs associated with restructuring activities and severance and nonroutine litigation; in the three months ended March 31, 2024, they include costs associated with the strategic review process, nonroutine litigation, standalone transition costs and shareholder activism. Expand FORWARD-LOOKING STATEMENTS This press release contains historical information, as well as forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act')) that involve known and unknown risks and relate to, among other things, future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, our future financial performance, our projected business results, or our projected capital expenditures. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, the reader can identify forward-looking statements by terminology such as 'may,' 'will,' 'should,' 'could,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'predicts,' 'targets,' 'potential,' or 'continue' or the negative of these terms or other comparable terminology. Any forward-looking statement speaks only as of the date of this presentation, and the Company undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by the Company include, but are not limited to, our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payers, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and healthcare professionals; potential disruptions or breaches of our or our vendors', payers', and other contract counterparties' information systems; the outcome of litigation; quality performance and ratings; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; and our ability to control costs, particularly labor and employee benefit costs. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this release are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company's website at
Yahoo
11-05-2025
- Business
- Yahoo
Enhabit (EHAB) Q1 Earnings Top Estimates
Enhabit (EHAB) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 42.86%. A quarter ago, it was expected that this provider of home health and hospice services would post earnings of $0.05 per share when it actually produced earnings of $0.04, delivering a surprise of -20%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Enhabit , which belongs to the Zacks Medical Services industry, posted revenues of $259.9 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.56%. This compares to year-ago revenues of $262.4 million. The company has not been able to beat consensus revenue estimates over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Enhabit shares have added about 2.9% since the beginning of the year versus the S&P 500's decline of -4.7%. While Enhabit has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Enhabit: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.09 on $267.14 million in revenues for the coming quarter and $0.37 on $1.07 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Natera (NTRA), is yet to report results for the quarter ended March 2025. The results are expected to be released on May 8. This genetic testing company is expected to post quarterly loss of $0.59 per share in its upcoming report, which represents a year-over-year change of -5.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Natera's revenues are expected to be $443.34 million, up 20.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Enhabit, Inc. (EHAB) : Free Stock Analysis Report Natera, Inc. (NTRA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
